Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

🏥 The U.S. FDA has granted Breakthrough Therapy Designation to Biogen's investigational drug salanersen for the treatment of spinal muscular atrophy (SMA).

💉 Salanersen is a novel antisense oligonucleotide designed to correct splicing of SMN2 pre-mRNA to increase production of survival motor neuron protein.

📅 The designation was announced on June 4, 2026, based on data from a Phase 1b study presented at recent scientific conferences in 2026.

👶 In the Phase 1b study, children with SMA who had suboptimal responses to prior gene therapy showed slowing of neurodegeneration and clinically meaningful improvements in motor function.

📉 The exploratory analysis revealed that some previously treated patients regained critical functions such as sitting and walking after receiving salanersen.

🧬 Salanersen is administered once-yearly via intrathecal injection and has the potential to offer high efficacy with a convenient dosing schedule.

🔬 Data from the Phase 1b study showed meaningful reductions of 75% in neurofilament light chain levels, a marker of ongoing neurodegeneration, at six months.

✅ All 24 participants in the Phase 1b study experienced increases on one or more endpoints, with 12 achieving at least one new WHO motor milestone.

🛡️ The drug was generally well-tolerated in the study, with most adverse events being mild to moderate in severity.

🌍 Biogen has licensed global development, manufacturing, and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc.

📋 The Phase 3 program consists of three global studies: STELLAR-1 (infants), SOLAR (teens and adults), and STELLAR-2 (post-gene therapy infants).

🔍 STELLAR-1 will evaluate salanersen in young, treatment-naïve infants under six weeks old with a genetic diagnosis of SMA.

👤 SOLAR will evaluate the drug in teens and adults aged 15–60 who are either treatment-naïve or previously treated with risdiplam.

🔬 STELLAR-2 is a randomized, double-blind study expected to begin recruitment in June 2026 for infants receiving presymptomatic gene therapy.

💰 The Phase 3 studies will evaluate the safety and efficacy of an 80 mg dose administered once-yearly across a broad spectrum of SMA patients.

📢 Biogen stated that this designation reflects the FDA's commitment to addressing the continued unmet need in spinal muscular atrophy.

⚠️ The press release includes standard forward-looking statements regarding potential clinical effects, regulatory approval, and commercialization risks.

🏢 Biogen is a leading biotechnology company founded in 1978 that pioneers innovative science to deliver new medicines for patients.

Bullish Signals
  • Biogen's investigational drug salanersen has received FDA Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA), a significant regulatory milestone that expedites development and review.
  • Exploratory analysis from the Phase 1b study demonstrated clinically meaningful improvements in motor function and slowing of neurodegeneration in children with SMA who had suboptimal responses to prior gene therapy.
  • In the Phase 1b study, all 24 participants treated with salanersen experienced increases from baseline on one or more endpoints, with 12 of 24 achieving at least one new WHO motor milestone.
  • Salanersen showed meaningful reductions (75%) in neurofilament light chain (NfL) levels, a marker of ongoing neurodegeneration, which were sustained throughout the follow-up period.
  • The drug is designed for once-yearly dosing with high potency due to its new chemistry, offering potential convenience and efficacy advantages over existing therapies.
  • Biogen has licensed global development, manufacturing, and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc., strengthening its SMA portfolio.
  • Three global Phase 3 studies (STELLAR-1, STELLAR-2, and SOLAR) are currently recruiting or expected to begin recruitment in June 2026 to further evaluate safety and efficacy across different patient populations.
  • RBC Capital raised its price target for Biogen (BIIB) to $227 from $222 and reaffirmed its Buy rating on the stock, reflecting positive investor sentiment.
Risk Factors
  • The Phase 3 program relies on three global studies, with STELLAR-2 recruitment not expected to begin until June 2026, indicating a long development timeline before potential commercialization.
  • Results from the early-stage Phase 1b study involving only 24 participants may not be indicative of full results or results from later stage or larger scale clinical trials.
  • The drug is still investigational and has not received regulatory approval; success in early stage clinical trials does not ensure regulatory approval for salanersen.
  • Biogen licensed the global development, manufacturing, and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc., creating a dependence on a third-party collaborator for the product's lifecycle.
  • The press release explicitly states that drug development and commercialization involve a high degree of risk and only a small number of research and development programs result in commercialization of a product.
  • Regulatory authorities may require additional information or further studies, or may fail to approve or delay approval of the drug candidate despite the Breakthrough Therapy Designation.
  • Positive results in the Phase 1b study may not be replicated in subsequent or confirmatory trials, and success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials.
Full Analysis
Biogen Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide, salanersen, for the treatment of spinal muscular atrophy (SMA). This designation is based on data from a Phase 1b study which demonstrated that salanersen can slow neurodegeneration and provide clinically meaningful improvements in motor function for children with SMA who previously received gene therapy but had suboptimal clinical outcomes. The exploratory analysis showed that participants treated with salanersen experienced reduced levels of neurofilament light chain, a marker of neurodegeneration, with reductions of up to 75% observed at six months following treatment initiation. Salanersen is designed as a novel intrathecally administered antisense oligonucleotide intended to correct splicing of SMN2 pre-mRNA to increase production of the survival motor neuron protein. The drug features a new chemistry that enables high potency and potential for once-yearly dosing, distinguishing it from current therapies that may require more frequent administration or have different mechanisms of action. In the Phase 1b study involving 24 participants aged 0.5 to 12 years, all treated individuals experienced increases on one or more endpoints, with 12 achieving at least one new World Health Organization motor milestone while maintaining previously documented milestones. The treatment was generally well-tolerated, with adverse events primarily being mild to moderate in severity, such as upper respiratory tract infections and pyrexia. The FDA's decision highlights the continued unmet need for effective treatments in SMA, a rare genetic neuromuscular disease affecting approximately 1 in 10,000 live births. Biogen has licensed global development, manufacturing, and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc., which discovered the compound. Moving forward, Biogen plans to advance three global Phase 3 studies: STELLAR-1 for treatment-naïve infants under six weeks old; SOLAR for teens and adults aged 15 to 60 years who are either treatment-naïve or previously treated with risdiplam; and STELLAR-2, expected to begin recruitment in June 2026, which will evaluate salanersen initiated approximately six months after onasemnogene abeparvovec-xioi gene therapy. These studies aim to establish the role of salanersen in the future SMA treatment landscape across a broad spectrum of individuals living with the disease.